© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 1 Arginine Cardio: Evidence-based reduction of blood pressure (1) L-Arginine is the precursor.

Slides:



Advertisements
Similar presentations
High Tech Plantation Method for multiplied yield Latest technology for processing & preserving Knowhow for various end products Unique R&D facilities.
Advertisements

Blood pressure reduction with statins Meta-analysis of randomised controlled trials P. Strazzullo 1, S.M. Kerry 2, A. Barbato 1,2, M. Versiero 1, L. D’Elia.
Vitamin D and Immunity. Vitamin D Has Two Principal Effects on the Immune System 1.Vitamin D enhances some innate defenses against bacterial, viral or.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
The complete formula to Enhance nitric oxide Reduce inflammation
By Hussam A.S. Murad Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad Department of Pharmacology.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Hypertension (high blood pressure) Dr. Fiona Gillan GP Registrar at Church End Medical Centre.
Ross Bryan Medical Student MS III Mercer University August 2012 Effect of Supplementation With High-Selenium Yeast on Plasma Lipids Annals of Internal.
OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.
Elise Wood Stress Management. Narrowing of the walls of the arteries Excessive plaque build up Disrupts blood flow Potential cardiovascular complications.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
Blood Pressure Control By Randomized Drug Group In ALLHAT William C. Cushman, Charles E. Ford, Paula T. Einhorn, Jackson T. Wright, Jr., Richard A. Preston,
Framingham meets genomics William P Castelli MD Director Framingham Cardiovascular Institute Adjunct-Associate Professor of Medicine Boston University.
Caitlin Cleary Biochemistry Spring ‘12. What is it? A type of arteriosclerosis characterized by changes in the endothelial lining and the formation of.
Vascular effects of PPAR  activation: Endothelial function.
The Effect of Chocolate Consumption on Cardiovascular Disease Risk Factors Stephanie Becker November 24, 2014.
JUSTIN BANNER CHIEF STRATEGY OFFICER. “FOR THEIR DISCOVERIES CONCERNING NITRIC OXIDE AS A SIGNALING MOLECULE IN THE CARDIOVASCULAR SYSTEM” 1998 Nobel.
Atherosclerosis CVS 1 Hisham Al Khalidi. Atherosclerosis.wmv.
Monocyte damaged endothelium macrophage foam cell lipid thrombocytes plaque oxidative stress smooth muscle cells 4 5 Gaviraghi et al., 1998 Lacidipine:
Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,
L-Arginine Clinical Trial Results of Study 18% increase in HDL 18% increase in HDL 40% decrease in triglycerides 40% decrease in triglycerides 8% glucose.
Cardiovascular Disease (CVD) A general term for diseases of the heart and/or blood __________ _____% of all deaths annually 2,600 American deaths each.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
High Tech Plantation Method for multiplied yield Latest technology for processing & preserving Knowhow for various end products Unique R&D facilities.
Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes Featured.
Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Vascular effects of PPAR  activation: Inflammation.
순환기질환 - 혈관, 림프관 -.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Rene Descartes: “I think; therefore I am.”. 3.3: Data Ethics Statistics Chap 3: Designing Experiments.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Does acute improvement of endothelial dysfunction.
Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Arginine Cardio: Evidence-based reduction of blood pressure (1)
Obesity Hypertension and Endothelial Dysfunction in Pediatric Patients
The American Heart Association Presented by Dr. Steven E. Nissen
Calcification burden of the femoropopliteal artery demonstrating progression from a healthy artery with no calcification (0) to advanced calcific deposits.
Oxford Niacin Trial.
Infusion of CSL112 increases total cholesterol efflux capacity (CEC) regardless of baseline functional apolipoprotein A-I (apoA-I) activity. Infusion of.
Problems Undermining Public Confidence in and Understanding of Research Failure to explain the importance of basic biomedical research to advances in.
The angiotensin converting enzyme (ACE) inhibitors, developed initially for blood pressure control, have become an essential part of the treatment of.
Focus: Lipids and the endothelium
Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.
The Hypertension in the Very Elderly Trial (HYVET)
William Insull, MD  The American Journal of Medicine 
Case 1: A 73-year-old white female with carotid disease
MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Why double blind, controlled randomized trials?
Figure 2 Imaging of atherosclerotic plaque burden
End point Net change with soy supplements vs control (95% CI) p
Chapter 28 Nutrition, Lifestyle, and Hypertension
Originally presented by Drs. Daniel Levy, Richard H. Grimm, Steven E
Section IV: The interaction of the RAS and lipids
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Correlation between endothelial function and hypertension
Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.
The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment William Insull, Jr, MD Professor of Medicine and Pediatrics,
Section 6: Update on lipid treatment guidelines
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Presentation transcript:

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 1 Arginine Cardio: Evidence-based reduction of blood pressure (1) L-Arginine is the precursor of Nitric Oxide L-Citrulline potentiates the bioavailability of L-arginine Arginine Cardio is the L-Arginine supplement that has the highest L-citrulline Content Nitric Oxide causes vasodilation and thereby reduces blood pressure.

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 2 Arginine Cardio: Evidence-based reduction of blood pressure (2) L-Arginine is not being marketed by pharmaceutical industry with a multi million dollar budget for promotion. Clinical trials with L-arginine to lower blood pressure have been performed by independent academic research institutions, with small research budgets. Therefore, patient numbers in clinical trials with L-arginine are comparatively small. However, there is a recent meta-analysis summarizing clinical trials with L-arginine.

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 3 Dong et al.; American Heart Journal randomized, double-blind, placebo-controlled trials involving 387 participants with oral L-arginine intervention ranging from 4 to 24 g/d […] Compared with placebo, L-arginine intervention significantly lowered systolic blood pressure by 5.39 mm Hg (95% CI −8.54 to −2.25, P =.001) and diastolic BP by 2.66 mm Hg (95% CI −3.77 to −1.54, P =.001). Arginine Cardio: Evidence-based reduction of blood pressure (3)

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 4 Dong et al.; American Heart Journal 2011 L-Arginine better Placebo better

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 5 Dong et al.; American Heart Journal 2011 L-Arginine better Placebo better

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 6 Dong et al.; American Heart Journal 2011

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 7 Arginine Cardio: Evidence-based reversal of atherosclerosis (1) Nitric Oxide has been known to protect from atherosclerosis ever since the Nobel Prize for Medicine was awarded for this finding in L-Arginine is the precursor of Nitric Oxide. Animal experiments have unequivocally proven in different models and in various laboratories around the world that L-arginine can reverse atheroslcerosis. Whilst no big, multinational studies could be performed with L-arginine due to lack of funding from public sources, multiple studies have shown reversal of endothelial dysfunction, the early clinical sign of atherosclerosis, by L-arginine. We have a collection of case reports that show reversal of atherosclerotic plaque in humans during a few months of L-arginine intake.

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 8 Böger et al., Atherosclerosis 1995; 117: 273 – 284 Study A: Prevention of Plaque Build-Up Design: 0 8 weeks Control Cholesterol Cholesterol + L-Arginine Results: Cholesterol Cholesterol; treated with L-arginine CONTROLCHOLESTEROL Carotid intimal plaque area [% of total intima] * CHOL. + L-ARGININE # (0) A. carotis

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 9 Böger et al., Circulation 1997; 96: Study B: Stopping the Progression of Plaque Build-Up Design: 0 10 weeks Control Cholesterol Results: 16 4 Cholesterol + L-Arginine Cholesterol Cholesterol + Lovastatin Control 0 weeks 16 4 Intimal plaque area (carotid artery) [%] % „Dietary L-arginine completely suppressed the aggravation of intimal plaque formation during the second part of the study Lovastatin treatment significantly reduced the progression of plaque formation but did not completely block it.“

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 10 Candipan et al., Arterioscler. Thromb. Vasc. Biol. 1996; 16: Study C: Reversal of Pre-Existing Plaque Design: 0 18 weeks Cholesterol Results: Cholesterol Cholesterol + L-Arginine 0 weeks Intimal plaque area (carotid artery) [%] „This is the first demonstration that restoration of NO activity can induce regression of preexisting intimal lesions and provides evidence that L-arginine therapy may be of potential clinical benefit “ Cholesterol 18 14

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 11

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 12

© Arginine Benefits LLC, 2013Author: Dr. Rainer BögerPage 13